Acquired partial and complete deletions of chromosome 5 (5q-,-5) are common cytogenetic anomalies associated with myelodysplasia (MDS) and acute myeloid leukemia (AML). A critical region of consistent loss at 5q31.1 (in >90% of cases) has led us and others to postulate the presence of a key negative regulator(s) of leukemogenesis. Although the interstitial deletion limits vary among patients, del(5) (q13q33) and de1(5)(q13q35) constitute major subsets. Furthermore, it is not rare to encounter deletions, translocations, or paracentric inversions involving 5 q l l to 5q13, which indicates inactivation or disruption of important gene(s) at that locus. In this report, we have localized a novel locus at 5q13.1 to a 2.0-Mb interval between the anonymous CQUIRED LOSS OF ALL (-5) or part of the long arm of human chromosome 5 (5q-chromosome) is seen in a wide range of myeloid disorders, including the 5q-syndrome refractory anemia (RA), preleukemic myelodysplasia (MDS), and therapy-induced or de novo MDS and acute myelogenous leukemia (AML).'" Typically, the constellation of preleukemic MDS and AML is distinct from the transfusion-dependent 5q-syndrome RA, in that the RA patients are relatively stable and the 5q-chromosome is the sole anomaly. There are no readily detectable cytogenetic differences between the 5q-chromosome of the various dysplastic states. High-resolution banding studies have identified the following common interstitial breakpoints: (l) del (5)(q13q35), (2) de1(5)(q13q33), (3) de1(5)(q22q33), and (4) de1(5)(q31q35). Of these, more than 45% of 5q-cases belong to subsets (1) and (2).4*' In physical terms, the deletions (5)(q13q35), (5)(q13q33), and -5 translate to hemizygosity for 60% to 75% and 100% of the long arm of chromosome 5.
Acquired partial and complete deletions of chromosome 5 (5q-,-5) are common cytogenetic anomalies associated with myelodysplasia (MDS) and acute myeloid leukemia (AML). A critical region of consistent loss at 5q31.1 (in >90% of cases) has led us and others to postulate the presence of a key negative regulator(s) of leukemogenesis. Although the interstitial deletion limits vary among patients, del(5) (q13q33) and de1(5)(q13q35) constitute major subsets. Furthermore, it is not rare to encounter deletions, translocations, or paracentric inversions involving 5 q l l to 5q13, which indicates inactivation or disruption of important gene(s) at that locus. In this report, we have localized a novel locus at 5q13.1 to a 2.0-Mb interval between the anonymous CQUIRED LOSS OF ALL (-5) or part of the long arm of human chromosome 5 (5q-chromosome) is seen in a wide range of myeloid disorders, including the 5q-syndrome refractory anemia (RA), preleukemic myelodysplasia (MDS), and therapy-induced or de novo MDS and acute myelogenous leukemia (AML).'" Typically, the constellation of preleukemic MDS and AML is distinct from the transfusion-dependent 5q-syndrome RA, in that the RA patients are relatively stable and the 5q-chromosome is the sole anomaly. There are no readily detectable cytogenetic differences between the 5q-chromosome of the various dysplastic states. High-resolution banding studies have identified the following common interstitial breakpoints: (l) del(5)(q13q35), (2) de1(5)(q13q33), (3) de1(5)(q22q33), and (4) de1(5)(q31q35). Of these, more than 45% of 5q-cases belong to subsets (1) and (2) .4*' In physical terms, the deletions (5)(q13q35), (5)(q13q33), and -5 translate to hemizygosity for 60% to 75% and 100% of the long arm of chromosome 5.
Invariant loss of 5q3 1.1 loci in more than 90% of all these cases indicates the existence of important regulatory gene(s) that may function recessively. While studies on a large number of AML and preleukemic MDS patients have identified the segment between the IL9 and EGRl genes to be the consistent region of loss,6-* two patients with the 5q-syndrome RA appear to retain all of the proximal 5q3 1.1 loci and show loss of a distal segment in between the glucocorticoid receptor and NKSFl genes,' implying the existence of two independent loci, the loss of which may contribute toward the two distinct clinical entities (Fig 1) . Occasional reports of a 5q-chromosome in which all of the 5q31 loci are retained with an identifiable deletion of chromosome 5qll to 5q13 or unbalanced translocations or paracentric inversion involving chromosome 5q14 to 543.5 are indicative of a third critical locus in the proximal part of the long arm of chromosome 5.10"4
Since the standard cytogenetic techniques do not readily detect subtle or complex translocations, little is known about the status of chromosome 5 sequences in patients who are monosomic for chromosome 5. If these patients harbor homozygous loss or unbalanced translocations of multiple critical loci, they may provide valuable clues for physical mapping of the critical gene(s). Availability of highly informative microsatellite polymorphisms from the human genome mapping initiative and development of a highly sensitive assay to detect allele loss in hematopoietic neoplasms allows rigorous molecular analysis of the restricted dysplastic material from patient^.".'^ In this report, we describe the physical localization of a locus to 5q13.1 and provide evidence for critical gene(s) that may be disrupted or inactivated by translocation and deletions in a subset of patients with anomalies of chromosome 5.
MATERIALS AND METHODS

Cases and cytogenetics.
Routine cytogenetic analyses were performed on all MDWAML patients seen at the Department of Hematology, M.D. Anderson Cancer Center, as detailed e1~ewhere.l~ Patient samples were obtained using approved protocols. Samples from patient UPN662 described in this study were from a 37-year-old woman who was diagnosed with de novo AML in October 1993 and presented with 67% blasts. Classical cytogenetics showed a pseudodiploid clone with 45 XX, de1(5)(q14), de1(7)(q21q31), del(9)(qllq22),add(ll)(p15),-16,andadd(17)(p11).InApril 1994, she was in clinical remission with no detectable cytogenetic abnormalities. Peripheral blood specimens collected at presentation (October 1993) and remission (April 1994) were used in the present study. Inter-Alu PCK. Unique single-copy sequences specific for chromosome S (from the somatic cell hybrid HHW 105) were amplified using the dual-primer Alu PCR. The primers and amplification conditions were as described by Liu et al." The same primers were used 10 amplify single-copy sequences present in the YACs. The amplification conditions were identical to the ones described earlier except that the annealing temperature was reduced to 37-C to increase yields.
FISH. Inter-Ah PCR products from the YACs and somatic cell hybrid HHW 105 were used to localize chromosome S sequences. The FISHs wcrc performed as detailed elsewhere." The slides were counterstained with propidium iodide (0.3 & n L ) or 4.6-Diamidino-2-phenyl-indole (DAPI; 0.1 pg/mL) in antifade solution of p-phenylenediamine and examined under a Nikon (Japan) microphot SA fluorescence microscope with a triple-band pass filter to visualize both the signals and cells simultaneously. Typically. 20 to 25 metaphases were analyzed by routine microscopy and permanent records were generated by the images captured in an image analyzer system (Perceptive Scientific Instruments. League City, TX).
RESULTS
Retentiort c$ both alleles of the 5q31 loci in patient
UfN662. During the course of our investigations on the critical AML tumor-suppressor locus, we detected retention of all of the Sq31.1 loci in the peripheral blood nucleated cells of a de novo AML patient (UPN662). Unlike the majority of the AML and MDS patients with 5q-chromosome studied in our laboratory and others, she showed heterozygosity for all the markers within the myeloid tumor-suppressor locus (AML) and the RA locus.
A systematic comparison of the dinucleotide polymorphisms in bands 5q23 to 5q31 between the peripheral blood samples collected at presentation and clinical remission is shown in Fig 2. The loci D5S421 and DSS404 map centromeric of the interleukin gene cluster on 5q23 to Sq31; the IL9 gene marks the most proximal gene within the myeloid tumor-suppressor locus that is retained in a small number of MDS/AML patients with 5q-chromosome; the D5S396 locus lies within the critical myeloid tumor-suppressor locus in Sq3 1. I , between the genes for IL9 and EGRI; the D5S519 locus maps between the colony-stimulating factor-I receptor and osteonectin genes within the distal RA locus (Fig I) . Surprisingly, the unique polymorphic pattern for each of the locus is identical between the samples collected at presentation and remission, denoting apparent retention of both copies of all the 5q21 to 5q31 loci.
Loss qf 5q13. I loci in patient UPN662. On further examination, both alleles of several of the Sq21 loci and distal 5q 13.3 loci (D5S644. D5S401. and D5S617) were also determined to be intact (Fairman and Nagarajan, unpublished results, December 1995). As seen in Fig 3, both alleles of the Sq13.1 loci D5S626, D5S620, and GATA-P18104 were retained in the presentation sample. The first marker for which we detect loss of heterozygosity is the anonymous locus AFBMB347YFY. Two other centromeric markers (D5S672 and D5S435) are deleted, indicating a contiguous deletion with a distal breakpoint between the GATA-P18104 and AFMB347YFY loci. An examination of the databases showed the loci GATA-P18104 and AFMB347YFY to be part of a YAC contig in the band Sq13.1 ( Table l ) .
The standard cytogenetic tests suggested that patient UPN662 carried a deletion of chromosome Sq 14 to 5q3 I. Retention of all of the Sq21 to 5q31 loci (Figs 2 and 3) Pres.
Rem. Loss of the 5q13.1 loci in de novo AML patient UPN662 presenting with 5q-chromosome. Dinucleotide polymorphism analysis was conducted on peripheral blood nucleated cells isolated at presentation (Pres.) and granulocytes in remission (Rem.). Polymorphic loci are denoted t o the left and missing alleles are indicated by arrow heads. Allele sizes are denoted in base pairs. Loss of heterozygosity for the AFBMB347YF9, D5S672, and D5S435 loci is detected by the absence of a second allele-specific amplification product. Retention of 2 alleles of GATA-P78704 and loss of an AFBMB347YF9 locus delineates the breakpoint between these 2 loci. Refer to Fig 1,  Table 1 , and Chumakov et aV5 for the chromosomal localization of these loci.
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showed that the deleted 5q segment may be retained elsewhere [del( 1 I)(p) or add( 17)(p)] on the genome. FISHs with chromosomes 5 and 17 specific painting probes, as well as 5q 13, 5q3 1 and 5q35 Y A G , showed that the chromosome 5q13 to 5q31 segment was inserted into 17p (L. Zhao et al, unpublished results, June 1994). This event appears to be accompanied by a submicroscopic deletion of the 5ql3.1 loci shown in Fig 3. We were unable to determine the proximal limit of this submicroscopic deletion due to the restricted amount of material and the poor quality of metaphases. 
Molecular delineation
D5S401
alleles of the 5ql3.1 loci. The remaining patients showed deletions that included all or some of the loci between D5S435 and D5S401 (Fig l) . Figure 4 summarizes the loss of heterozygosity analysis of these cases for the 5q13.1 to 5q2 1 loci. Patients no. 1 to 9 harbor large deletions spanning the entire 5q13.1 loci, as well as other 5q21 and 5q31 loci, which suggests that these are large contiguous interstitial deletions or a complete loss of a chromosome 5. The proximal limit resides between the GATA-P18104 and D5S672 in the case of a RA patient no. IO. Patient no. 11 showed retention of both alleles of D5SI 12 and loss of the D5S672, AFMB347YF9, and several other telomeric loci. Results on UPN662 are represented as patient no. 12. Patients no. IO and 12 allow us to delineate the smallest region of overlap to be between the D5S672 and the GATA-P18104 loci.
The diagnosis and cytogenetic characteristics of these paPatient number t This is UPN662.
~ ~~ tients are summarized in Table 2 . The cases are ordered based on their molecular delineations detailed in Fig 4, ie, patients no. 1 to 9 had large contiguous deletions. Further subdivision of this group between the ones with interstitial deletion and monosomy 5 categories showed patients no. 1 to 4 to be 5q-and no. 5 to 9 to be monosomic for chromosome 5. Table 2 further reveals the diagnostic classification of these cases ranged from an unusual case of RA with multiple cytogenetic anomalies (patient no. 1) to a rare AML patient with 5q-chromosome as the sole anomaly (patient no. 4). None of the monosomy 5 patients retained any of these loci on the marker chromosomes (patients no. 5 to 9). Among the patients whose proximal breakpoint resides within the 5q13.1 locus, patient 10 was a case of transfusiondependent RA with the 5q-chromosome as the sole anomaly. Patient no. 1 1 , who transformed to AML following an antecedent MDS, had a proximal breakpoint between the D5S112 and D5S672 loci. The AFMB347YF9 locus and the D5S620D5S626/ D5S641 cluster flank an inversion coupled translocation in an AML cell line. The delineation of the critical 5q13.1 region could be further characterized by identification of a model AML cell line. Previous karyotypic analysis had determined that the AML cell line ML3 carried a normal chromosome 5, de1(5)(q13q35) chromosome, and a der(3), which contains all of the deleted chromosome 5q13 to 5q35 materiaLz3 Analogous to UPN662, this cell line retains heterozygosity for all of the microsatellite and restriction fragment-length polymorphisms in the chromosome 5q21 to 5q35 region tested to date (Fairman and Nagarajan, unpublished results, May 1994).
FISH results depicted in Fig 5A demonstrate that there are three distinct chromosomes with chromosome 5 sequences: (l) the normal chromosome 5; (2) the 5q-chromosome with deletion of 5q13 to 5q35; and (3) a large der(3) chromosome, with insertion of chromosome 5 sequences. The condition of the inserted 5q13 to 5q35 segment on the derivative chromosome was investigated with nonchimeric YACs. The YAC 880g9, which lies within the AML tumorsuppressor loeus,8 and the YAC 746b2, which is telomerie of the nucleophosmin locus in 5q35,24 were used in these studies. The results shown in Fig 5B allow us to make several conclusions: (1) both the 5q3 I and 5q35 YACs are excluded from the 5q-chromosome; (2) the deleted 5q13 to 5q35 is inserted in an inverted orientation on a der(3) chromosome as the signal from YAC 746b2 (5q35) is proximal to the signal from the YAC 88089 (5q31); and (3) the AML tumorsuppressor locus and the RA locus are grossly intact on the der(3) chromosome.
To define the 5q13.1 breakpoint, inter-Ah PCR products from YACs were hybridized to metaphase preparations from the ML3 cells. The results obtained with the two of the nonchimeric YACs are shown in Fig 6. The inter-Alu PCR products from the YAC 9561311 containing the locus D5S62O/D5S626/D5S641 show a detectable signal on the der(3) chromosome containing the 5q sequences (Fig 6.4) . Figure 6B shows identification of the chromosome 5 sequences on the same metaphase (Fig 6A) with a chromosome 5-specific painting probe. In contrast to Fig 6A, the YAC 745a9, which spans the AFMB347YF9 locus, hybridizes to homologous sequences on the normal chromosome 5 and close to the telomere of the q arm of the 5q-chromosome (Fig 6C) . The sequences present in the YAC 745a9 are centromeric of the chromosomal segment inserted into the der(3) chromosome, implying that the 5q13.1 breakpoint is telomeric of the AFMB347YF9 locus analogous to UPN662.
Results described in Fig 6, taken together with the retention of both alleles of GATA-P18104 in UPN662, allow us to narrow down the critical 5q13.1 locus between these two loci. Data shown in Table 1 reveal that the cluster D5S641/ D5S620D5S626 contained within the 1.05-Mb YAC 965b11 spans 3.14 cR units based on radiation hybrid analyses. Thus, the physical distance between the loci GATA-P18104 and AFMB347YF9 corresponding to 6.1 cR units can be estimated to be less than 2.0 Mb.
DISCUSSION
Cytogenetic and molecular analyses by a number of groups have identified invariant loss of band 5q31.1 in more than 150 patients with the 5q-chromosome, and the deletions extend to 5 q l l to 5q13 in a significant proportion (>45%) of these cases. Additionally, there have been sporadic descriptions of translocations or deletions of the bands 5 q l l to 5q13. Three cases of unbalanced translocations of chromosome bands 5ql1 to chromosome 7,13 a case of MDS with t(5;21)(q13.l;q22) involving the runt homolog on chromosome 22,25 a case each of paracentric inversion involving 5q14 to 5q35, and t(5; 17), and three cases of three-way translocations involving 5, 17, 12, and 5, 17, and 18 have been identified;"-12 a single case of RA with a 5q-chromosome showed retention of all of the 5q31 10ci.l~ Thus far, there have been no systematic attempts to delineate the interstitial 5q deletions using the PCR-based microsatellite polymorphism analyses to detect allele loss. Availability of a large number of such markers from the genome mapping efforts15 facilitates this approach and overcomes the technical problems of minimal patient material, as well as lack of informativeness of polymorphic loci. The results described in the present study demonstrate disruption of a critical 5q13.1 region by translocation or deletion. In UPN662, this is characterized by a submicroscopic deletion coupled to juxtapositioning of the chromosome 5q13 to 5q31 segment to chromosome 17p, which may be analogous to the previously reported unbalanced t(5; 17) in therapy-induced MDS . ' ' Involvement of the same locus in the inversion seen in the ML3 cell line suggests that this locus may also be affected in the previously described paracentric inversions of 5q14 to 5q35 associated with secondary MDS." The translocation of the 5q13.1 to 5q35 segment in an inverted orientation in the ML3 cells results in a disruption of a 5q13.1 locus, which is telomeric of the sequences present in the YAC 745a9 and centromeric of the YAC 965b11. Similarly, the 5q13.1 breakpoint described by Nucifora et al in a case of t(5; 21)(q13.l;q22) is flanked by YACs from the D5S112 and D5S617 loci, suggesting the same fusion partner may be involved in all of these cases (Roulston and Nagarajan, unpublished results, September 1995). Alternatively, there may be more than one critical gene within this interval. Nonetheless, an integration of these results indicates that a novel locus, which maps telomeric of the AFMB347YF9 locus and centromeric of the marker GATA-P18104, is a site of inactivationfactivation by deletions or translocations. The physical distance between these two loci is estimated to be less than 2.0 Mb based on the cR units of radiation hybrid map available from the databases ( Table 1) .
The finding on UPN662 is an important example of the need for rigorous molecular analysis for accurate interpretation of the standard cytogenetic findings. Interestingly, the proximal breakpoints within the 5q13.1 region are seen in two other cases (Fig 3, patients no. 10 and 11) with interstitial deletion of chromosome 5. As suggested by Thangavelu et al,I3 translocations involving 5qll to 5q13 regions may be underreported due to the resemblance between a 5q-chromosome and one harboring a small translocated autosomal segment at 5q 13.1.
Molecular cloning of genes residing at chromosomal breakpoints in myeloid leukemias has provided evidence for submicroscopic deletions accompanying the juxtapositioning of critical genes to variant loci.26 There appears to be a repertoire of gene activationfinactivation events in MDS and myeloid neoplasms. The critical locus disrupted in the cases described here may also be lost in patients with 5q-chromosome belonging to the de1(5)(q13q33) and del(S)(q13q35) subsets and may be a possible tumor-suppressor. Positional cloning of this locus will be facilitated by the characterization of the translocations, analogous to the isolation of the NF1 tumor-suppressor gene on chromosome 17q12, which was pinpointed by a couple of rare cases with translocation coupled deletion of the candidate gene.27.28 Availability of high-density maps and YAC contigs has equipped us with the required preliminary reagents for these endeavors.
The long arm of human chromosome 5 contains 4.5% of the haploid genome, and the physical loss ranging from 60% to 75% to 100% of this chromosome associated with the deletions 5q13 to 5q33, 5q13 to 5q35, and monosomy 5 cases, renders room for point mutations at more than a single locus in the remaining "normal" chromosome 5. We have previously described such a case of MDS in a patient who had lost the entire 5ql l to 5q31 loci and harbored a submicroscopic deletion of the CSFIR locus on the 5q-chromosome.29 Localization of a novel locus in the band 5q13.1 in this report in conjunction with the two other previously characterized loci on 5q3 1.1 are the necessary first steps in the isolation of the genes that may act singly or in combination. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
